Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31700607 | 1.00 | ERN1 (0.52) | ERN1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL698742 | 0.84 | KDM4E (0.61) | ERN1KDM4EALDH1A1MAPTHPGD | |
| Ethyl Acetate SCHEMBL29014943 | 0.82 | ALDH1A1 (0.41) | ERN1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL3723645 | 0.81 | KDM4E (0.58) | ERN1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL3170417 | 0.80 | METAP2 (0.48) | ERN1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL438501 | 0.80 | ALDH1A1 (0.57) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL30892252 | 0.80 | ALDH1A1 (0.57) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL27675448 | 0.79 | METAP2 (0.58) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL700922 | 0.79 | METAP2 (0.58) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL2722234 | 0.79 | CA1 (0.50) | KDM4EALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024296-B | Preparation method of labetalol hydrochloride | 四川伊诺达博医药科技有限公司 | 2026-03-17 | — | — | CN | disclosed |
| US-20250319056-A1 | METHODS FOR TREATING CANCER | UNIV INDIANA TRUSTEES (US) | 2025-10-16 | — | — | US | disclosed |
| WO-2025121436-A1 | BICYCLIC HETEROCYCLIC COMPOUND AND FUNGICIDE FOR AGRICULTURAL AND HORTICULTURAL USE CONTAINING SAME AS ACTIVE INGREDIENT | 三井化学クロップ＆ライフソリューション株式会社 | 2025-06-12 | — | — | WO | disclosed |
| US-20240327442-A1 | CONTROLLING METAL-ORGANIC FRAMEWORK MORPHOLOGY THROUGH COORDINATIVE MIMICRY | ExxonMobil Technology and Engineering Company | 2024-10-03 | — | — | US | disclosed |
| EP-4380944-A1 | CONTROLLING METAL-ORGANIC FRAMEWORK MORPHOLOGY THROUGH COORDINATIVE MIMICRY | The Regents of the University of California (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118076618-A | Control of metal-organic framework morphology by coordination modeling | 加利福尼亚大学董事会 | 2024-05-24 | — | — | CN | disclosed |
| CN-117024296-A | Preparation method of labetalol hydrochloride | 四川伊诺达博医药科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116253698-A | 5-phenyl-1, 3,2, 4-dioxathiazole 2-oxide and preparation thereof | 张家港市国泰华荣化工新材料有限公司 | 2023-06-13 | — | — | CN | disclosed |
| WO-2023014513-A1 | CONTROLLING METAL-ORGANIC FRAMEWORK MORPHOLOGY THROUGH COORDINATIVE MIMICRY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-09 | — | — | WO | disclosed |
| CN-113081968-A | Oral gel powder for treating livestock and poultry diseases and preparation method thereof | 泰州骏道立同生物科技有限公司 | 2021-07-09 | — | — | CN | disclosed |
| EP-2336113-A1 | CRTH2 Receptor Ligands for Medical Use | 7TM Pharma A/S (DK) | 2011-06-22 | — | — | EP | disclosed |
| US-20090099189-A1 | CRTH2 Receptor Ligands For Medicinal Uses | 7TM PHARMA A/S (DK) | 2009-04-16 | — | — | US | disclosed |
| US-20080234370-A1 | Calcium receptor antagonists; 3-{3,4-Difluoro-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid; bone disorders; hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing,arthritis, Paget's disease, humoral hypercalcemia, osteoporosis | MARQUIS ROBERT W | 2008-09-25 | — | — | US | disclosed |
| US-20080234370-A1 | Calcium receptor antagonists; 3-{3,4-Difluoro-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid; bone disorders; hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing,arthritis, Paget's disease, humoral hypercalcemia, osteoporosis | MARQUIS ROBERT W | 2008-09-25 | — | — | US | disclosed |
| US-20080234370-A1 | Calcium receptor antagonists; 3-{3,4-Difluoro-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid; bone disorders; hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing,arthritis, Paget's disease, humoral hypercalcemia, osteoporosis | MARQUIS ROBERT W | 2008-09-25 | — | — | US | disclosed |
| EP-1713767-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1758579-A1 | CRTH2 RECEPTOR LIGANDS FOR MEDICINAL USES | 7TM Pharma A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| EP-1713767-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005115382-A1 | CRTH2 RECEPTOR LIGANDS FOR MEDICINAL USES | 7TM PHARMA A/S (DK) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005077892-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234370-A1 | Calcium receptor antagonists; 3-{3,4-Difluoro-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid; bone disorders; hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing,arthritis, Paget's disease, humoral hypercalcemia, osteoporosis | PTH1R, CASR, CALCR | ERN1 2306/4885KDM4E 3299/4885ALDH1A1 2851/4885 |
| US-20240327442-A1 | CONTROLLING METAL-ORGANIC FRAMEWORK MORPHOLOGY THROUGH COORDINATIVE MIMICRY | TPR, CA4, CA2 | ERN1 4781/4885KDM4E 868/4885ALDH1A1 2513/4885 |
| US-20090099189-A1 | CRTH2 Receptor Ligands For Medicinal Uses | HRH1, HRH2, HRH3 | ERN1 3739/4885KDM4E 4637/4885ALDH1A1 532/4885 |
| US-20250319056-A1 | METHODS FOR TREATING CANCER | HSP90AB1, HSP90B1, HSP90AB2P | ERN1 2613/4885KDM4E 3488/4885ALDH1A1 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.